Improper input validation in Sas Drug Development

CVE-2007-6763

SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources by pressing a back or forward button in a web browser.

Vulnerability class: Drupalgeddon 2 (CVE-2018-7600)

Published · last modified .

CVSS v3 metric

CVSS v3 base score 8.8 (High). Vector: CVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H.

EPSS exploit prediction

EPSS: 0.013 (69.7th percentile), scored .

Low probability of exploitation in the next 30 days, but still tracked. 70th percentile — 69.7% of CVEs in the catalogue have a lower EPSS than this one. How to read EPSS.

EPSS trend (30 days)EPSS over the last 30 days for CVE-2007-6763: held from 0.013 to 0.013.

EPSS over last 30 days · oldest: 0.013 · newest: 0.013 · change: 0.000

Affected products

Weakness classification (CWE)

References

Frequently asked questions

What is CVE-2007-6763?
CVE-2007-6763 is a high-severity vulnerability in Sas Drug Development, classified under Improper Input Validation. CVSS score: 8.8/10. Published 2019-07-31.
How severe is CVE-2007-6763?
High severity. CVSS v3 base score is 8.8 out of 10.